• ABOUT
Product description
1.
Implementation
a. NMR platform upgrade
b. De novo NMR platform design
Save money and implement only what you need
2.
Consumables
a. Screening chemical kits, pre-dosed
b. Affinity determination kits
Use our proprietary library or ask for custom library
3.
Software
a. Automated screening analysis
b. Automated affinity determination analysis
Simple and quick, no expertise needed
NexMR build upon a
team of experts
NexMR is an ETH Zurich spin-off offering key-in-hands solutions to improve the throughput and optimize the resources of NMR-drug discovery pipelines.
NexMR’s technology is designed to address challenging targets
• ADVANTAGES
Address your drug discovery
challanges with NexMR
——
Early stage drug discovery
——
Sensitivity-enhanced NMR accelerate experimental turnaround
——
Determine hit affinities by NMR with Isotope labelling
——
Information at the atomic scale
Faster
30-50-fold
Cheaper
Compatible with benchtop NMR
Simpler
Designed for lab technicians
Economical
Reduce sample concentration by 10-100-fold
About founders
Dr Félix Torres
CEO of NexMR
Felix is a PharmD and PhD in Chemistry from ETH Zürich. He developed tools for structural biology and drug discovery for the last 7 years.
Matthias Bütikofer
CSO of NexMR
Matthias is a MSc in chemistry from ETH Zürich. He is also a lab expert with experience working at the chemistry department of Roche.
Prof Roland Riek
Scientific Advisor
Roland is a tenured Prof at ETH Zürich. His work pioneered the study of biomolecules by NMR in particular amyloid fibrils.
Anil Sethi
Board Member
Anil is a serial entrepreneur, teacher at ETH Zürich, and advisor is a number of technology companies.
• CONTACT US
Interested in our
services?
You fill out an application on the website
We will contact you within 1-2 business days
After a personal conversation, we prepare a personal application for you
